Cerbios, Oncotec Join ADC Collaboration
CMC Biologics, a Copenhagen, Denmark-based contract biologics manufacturer, and IDT Biologika GmbH, a Dessau-Rosslau, Germany-based life-science company, have added Cerbios-Pharma SA, a Lugano, Switzerland-based biologics active pharmaceutical ingredient (API) manufacturer, and Oncotec Pharma Produktion GmbH, a contract manufacturing organization also based in Dessau-Rosslau, to Proveo, CMC and IDT Biologika’s strategic collaboration for providing a solution for the process development and manufacture of antibody drug conjugates (ADCs).
Within the Proveo partnership, CMC Biologics provides monoclonal antibody production, and Cerbios performs process development and manufacture of the cytotoxic drug-linker payload and the conjugation services of the ADC drug substance. Oncotec provides aseptic fill and lyophilization of the ADC drug product, and IDT Biologika performs analytical and quality services, supply chain, and secondary packaging through to ready-to-deliver final drug product. These services will be available in early 2017. In addition, as part of the integrated offering, the Proveo partnership provides project management, supply-chain systems, and quality systems.
Source: Cerbios-Pharma SA